1807988-47-1
中文名稱
IITZ-01
英文名稱
IITZ-01
CAS
1807988-47-1
分子式
C26H23FN8O
分子量
482.51
MOL 文件
1807988-47-1.mol
更新日期
2024/11/11 15:37:45
1807988-47-1 結(jié)構(gòu)式
基本信息
中文別名
N2-(4-(1H-苯并[D]咪唑-2-基)苯基)-N4-(4-氟苯基)-6-嗎啉代-1,3,5-三嗪-2,4-二胺 英文別名
IITZ-01CS-2857
Autophagy inhibitor IITZ-01
AUTOPHAGY INHIBITOR
IITZ 01
IITZ01
AUTOPHAGY INHIBITOR IITZ-01
IITZ 01
IITZ01
N-[4-(1H-Benzimidazol-2-yl)phenyl]-N'-(4-fluorophenyl)-6-(4-morpholinyl)-1,3,5-triazine-2,4-diamine
1,3,5-Triazine-2,4-diamine, N2-[4-(1H-benzimidazol-2-yl)phenyl]-N4-(4-fluorophenyl)-6-(4-morpholinyl)-
物理化學性質(zhì)
沸點747.0±70.0 °C(Predicted)
密度1.420±0.06 g/cm3(Predicted)
儲存條件Keep in dark place,Inert atmosphere,2-8°C
溶解度DMSO:100.0(Max Conc. mg/mL);207.24(Max Conc. mM)
酸度系數(shù)(pKa)11.55±0.10(Predicted)
形態(tài)Solid
顏色White to off-white
IITZ-01價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | HY-112897 | IITZ-01 IITZ-01 | 1807988-47-1 | 5mg | 700元 |
| 2024/11/08 | HY-112897 | IITZ-01 IITZ-01 | 1807988-47-1 | 10mM * 1mLin DMSO | 740元 |
| 2024/11/08 | HY-112897 | IITZ-01 IITZ-01 | 1807988-47-1 | 10mg | 1200元 |
常見問題列表
生物活性
IITZ-01 是一個具有抗腫瘤活性的、有效的親溶酶體的自噬抑制劑，其對 PI3Kγ 的 IC50 值為 2.62 μM。靶點
|
PI3Kγ 2.62 μM (IC 50 ) |
Autophagy
|
體外研究
IITZ-01 (0-2 μM, 24 h) enhances autophagosomes formation as indicated by increased expression of LC3-II levels time- and dose-dependently in triple-negative breast cancer (TNBC) cell lines (MDA-MB-231 and MDA-MB-453). IITZ-01 also demonstrates potent autophagy inhibitory activity in other breast, lung, and colon cancer cells.
Western Blot Analysis
| Cell Line: | Triple-negative breast cancer (TNBC) cell lines (MDA-MB-231 and MDA-MB-453). |
| Concentration: | 0-2 μM. |
| Incubation Time: | 24 hours. |
| Result: | Enhanced autophagosomes formation as indicated by increased expression of LC3-II levels. |
體內(nèi)研究
IITZ-01 (45 mg/kg, i.p. every alternate day for 4 weeks) inhibits average breast tumor growth when compared with control from third day of treatment in triple-negative breast tumor models in mice.
| Animal Model: | MDA-MB-231 (TNBC)/green fluorescent protein (GFP) orthotropic breast cancer xenografts were developed in CrTac:NCr-Foxn nu BALB/c female nude mice. |
| Dosage: | 45 mg/kg. |
| Administration: | Intraperitoneal every alternate day for 4 weeks. |
| Result: | Inhibited average breast tumor growth when compared with control from third day of treatment. |